JP2018531987A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531987A5 JP2018531987A5 JP2018529516A JP2018529516A JP2018531987A5 JP 2018531987 A5 JP2018531987 A5 JP 2018531987A5 JP 2018529516 A JP2018529516 A JP 2018529516A JP 2018529516 A JP2018529516 A JP 2018529516A JP 2018531987 A5 JP2018531987 A5 JP 2018531987A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- tautomer
- stereoisomer
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000000623 heterocyclic group Chemical group 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 21
- 239000001257 hydrogen Substances 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 125000000547 substituted alkyl group Chemical group 0.000 claims 18
- 150000002431 hydrogen Chemical class 0.000 claims 17
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000004452 carbocyclyl group Chemical group 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000002252 acyl group Chemical group 0.000 claims 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000003107 substituted aryl group Chemical group 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000002837 carbocyclic group Chemical group 0.000 claims 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 108010016626 Dipeptides Proteins 0.000 claims 2
- 101150113681 MALT1 gene Proteins 0.000 claims 2
- 102000057613 Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Human genes 0.000 claims 2
- 108700026676 Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102000046016 B-Cell CLL-Lymphoma 10 Human genes 0.000 claims 1
- 108700024832 B-Cell CLL-Lymphoma 10 Proteins 0.000 claims 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 1
- 101150074953 BCL10 gene Proteins 0.000 claims 1
- 102000007443 Deubiquitinating Enzyme CYLD Human genes 0.000 claims 1
- 108010086291 Deubiquitinating Enzyme CYLD Proteins 0.000 claims 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021135770A JP2021193093A (ja) | 2015-08-28 | 2021-08-23 | Ｍａｌｔ１阻害剤およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562211629P | 2015-08-28 | 2015-08-28 | |
| US62/211,629 | 2015-08-28 | ||
| US201562256672P | 2015-11-17 | 2015-11-17 | |
| US62/256,672 | 2015-11-17 | ||
| PCT/US2016/049038 WO2017040304A1 (en) | 2015-08-28 | 2016-08-26 | Malt1 inhibitors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021135770A Division JP2021193093A (ja) | 2015-08-28 | 2021-08-23 | Ｍａｌｔ１阻害剤およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018531987A JP2018531987A (ja) | 2018-11-01 |
| JP2018531987A5 true JP2018531987A5 (enExample) | 2019-10-03 |
| JP6989505B2 JP6989505B2 (ja) | 2022-01-05 |
Family
ID=58188144
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529516A Active JP6989505B2 (ja) | 2015-08-28 | 2016-08-26 | Ｍａｌｔ１阻害剤およびその使用 |
| JP2021135770A Pending JP2021193093A (ja) | 2015-08-28 | 2021-08-23 | Ｍａｌｔ１阻害剤およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021135770A Pending JP2021193093A (ja) | 2015-08-28 | 2021-08-23 | Ｍａｌｔ１阻害剤およびその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10711036B2 (enExample) |
| EP (1) | EP3341007B1 (enExample) |
| JP (2) | JP6989505B2 (enExample) |
| WO (1) | WO2017040304A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3736277A1 (en) | 2016-07-29 | 2020-11-11 | Lupin Limited | Substituted thiazolo-pyridine compounds as malt1 inhibitors |
| WO2018020474A1 (en) | 2016-07-29 | 2018-02-01 | Lupin Limited | Substituted thiazolo-pyridine compounds as malt1 inhibitors |
| EP3495348A4 (en) * | 2016-07-29 | 2020-01-22 | Toray Industries, Inc. | GUANIDINE DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES |
| KR20200105678A (ko) * | 2017-12-28 | 2020-09-08 | 더 제너럴 하스피탈 코포레이션 | Cbm 시그날로좀 복합체 표적화는 조절 t 세포의 종양 미세환경에 대한 염증유발을 유도함 |
| WO2019159097A1 (en) * | 2018-02-14 | 2019-08-22 | Sun Pharmaceutical Industries Limited | Crystalline polymorphic forms of acalabrutinib |
| AU2019289223B2 (en) * | 2018-06-18 | 2023-09-21 | Janssen Pharmaceutica Nv | Pyrazole derivatives as MALT1 inhibitors |
| EA202190055A1 (ru) * | 2018-06-18 | 2021-04-23 | Янссен Фармацевтика Нв | Производные пиразола в качестве ингибиторов malt1 |
| EP3863625A4 (en) * | 2018-10-09 | 2022-06-29 | The Research Institute at Nationwide Children's Hospital | Anticancer rocaglamide derivatives |
| CN111358959B (zh) * | 2019-10-10 | 2021-03-26 | 鹿文葆 | Roquin1蛋白及其编码基因在制备抑制肿瘤的药物中的应用 |
| CN111686111B (zh) * | 2020-06-09 | 2023-06-13 | 南方医科大学 | Malt1蛋白酶抑制剂在制备非小细胞肺癌治疗药物中的应用 |
| WO2022081967A1 (en) * | 2020-10-16 | 2022-04-21 | Rheos Medicines, Inc. | Malt1 modulators and uses thereof |
| EP4284804A1 (en) | 2021-01-26 | 2023-12-06 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders |
| CN113057957A (zh) * | 2021-03-30 | 2021-07-02 | 福建中医药大学 | 葛杜宁及其衍生物在制备抗氧化药物和/或化妆品及治疗类风湿性关节炎药物中的用途 |
| CN113024565B (zh) * | 2021-03-31 | 2022-09-13 | 上海启甄环境科技有限公司 | 一种放射性同位素碳-14标记依鲁替尼及其合成方法 |
| WO2023149945A1 (en) * | 2022-02-03 | 2023-08-10 | Purdue Research Foundation | Peptidomimetic inhibitors of protein n-terminal methyltransferase 1, composition, and method of use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210272A (en) | 1990-02-16 | 1993-05-11 | Prototek, Inc. | Process for forming a fluoromethyl ketone |
| CA2253835A1 (en) | 1996-06-18 | 1997-12-24 | Kent Alan Berryman | Process for the preparation of chiral keto-heterocycles of basic amino acids |
| KR20020029419A (ko) | 1999-07-07 | 2002-04-18 | 다비드 에 질레스 | 퀴나졸린 유도체 |
| JP5479105B2 (ja) | 2007-11-05 | 2014-04-23 | 国立大学法人佐賀大学 | 新規ユビキリン結合性小分子 |
| US8993758B2 (en) | 2010-11-22 | 2015-03-31 | Board Of Regents Of The University Of Nebraska | Substituted quinoxalines and uses thereof |
| EA201590916A1 (ru) | 2012-11-09 | 2016-02-29 | Корнэлл Юниверсити | Низкомолекулярные ингибиторы malt1 |
| EP4649963A3 (en) | 2014-04-14 | 2026-05-13 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| JP6545197B2 (ja) | 2014-05-28 | 2019-07-17 | ノバルティス アーゲー | 新規なピラゾロピリミジン誘導体およびｍａｌｔ１阻害剤としてのその使用 |
| US10689366B2 (en) | 2016-11-01 | 2020-06-23 | Cornell University | Compounds for MALT1 degredation |
-
2016
- 2016-08-26 WO PCT/US2016/049038 patent/WO2017040304A1/en not_active Ceased
- 2016-08-26 EP EP16842694.8A patent/EP3341007B1/en active Active
- 2016-08-26 JP JP2018529516A patent/JP6989505B2/ja active Active
- 2016-08-26 US US15/755,951 patent/US10711036B2/en active Active
-
2021
- 2021-08-23 JP JP2021135770A patent/JP2021193093A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7745892B2 (ja) | Ｎ４－ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途 | |
| KR102566924B1 (ko) | 케모카인 수용체 조절제 및 이의 용도 | |
| FI4073065T3 (fi) | Uusia metyylikinatsolinonijohdannaisia | |
| CN111372592A (zh) | N4-羟基胞苷及衍生物和与其相关的抗病毒用途 | |
| JP2016053078A (ja) | がん及び非新生物性状態の治療方法 | |
| KR102536156B1 (ko) | N-[5-(아미노술포닐)-4-메틸-1,3-티아졸-2-일]-n-메틸-2-[4-(2-피리디닐)-페닐]-아세트아미드 유리 염기 반수화물, 그의 제조 방법 및 용도 | |
| JP2017511360A5 (enExample) | ||
| JP2014503567A5 (enExample) | ||
| JP2009536620A5 (enExample) | ||
| EP4327877A3 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| JP2019515908A5 (enExample) | ||
| US20230063768A1 (en) | Immunophilin binding agents and uses thereof | |
| JP2015500885A5 (enExample) | ||
| TW201619142A (zh) | 利用替唑尼特（ｔｉｚｏｘａｎｉｄｅ）、其類似物或鹽類之前驅藥的組成物及治療方法 | |
| JP2013540114A5 (enExample) | ||
| JP2013514980A5 (enExample) | ||
| JP2016540803A5 (enExample) | ||
| TW200529811A (en) | HIV protease inhibiting compounds | |
| JP2019519512A5 (enExample) | ||
| JP2005526024A5 (enExample) | ||
| AU2020221247B2 (en) | Formulations comprising heterocyclic protein kinase inhibitors | |
| JP2017532316A5 (enExample) | ||
| JP2015522592A5 (enExample) | ||
| RU2015101702A (ru) | Фармацевтически активные соединения | |
| US9676727B2 (en) | Myxovirus therapeutics, compounds, and uses related thereto |